Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 1191 results for pain

  1. Suicide prevention (QS189)

    This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.

  2. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.

  3. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  4. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  5. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

  6. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

  7. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

  8. Endoscopic sleeve gastroplasty for obesity (IPG783)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

  9. Photodynamic endometrial ablation (IPG47)

    Evidence-based recommendations on photodynamic endometrial ablation. This involves using a light-sensitive chemical and laser to destroy the endometrium.

  10. Preventing suicide in community and custodial settings (NG105)

    This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

  11. Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)

    Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.

  12. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

  13. Prosthetic intervertebral disc replacement in the cervical spine (IPG341)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  14. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  15. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.